NCT03464526View on ClinicalTrials.gov

A Study of the Efficacy and Safety of Orvepitant in Subjects With Pruritus Associated With Atopic Dermatitis

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2018

Primary Completion Date

June 30, 2019

Study Completion Date

October 31, 2019

Conditions
PruritusAtopic Dermatitis
Interventions
DRUG

Orvepitant

Tablet, once daily, oral

DRUG

Placebo

Tablet, once daily, oral

Sponsors
All Listed Sponsors
lead

Nerre Therapeutics Ltd.

INDUSTRY

NCT03464526 - A Study of the Efficacy and Safety of Orvepitant in Subjects With Pruritus Associated With Atopic Dermatitis | Biotech Hunter | Biotech Hunter